Anti-CD19抗体のパイプライン・インサイト2017

◆英語タイトル:Anti-CD19 Antibody -Pipeline Insights, 2017
◆商品コード:DIMR201696
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年01月
◆ページ数:約60
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥138,750見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、世界におけるAnti-CD19抗体のパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・Anti-CD19抗体の概要
・Anti-CD19抗体のパイプライン概要
・企業別開発中のAnti-CD19抗体
・後期治験段階の薬剤(Filed & Phase III):比較分析
・中期治験段階の薬剤(Phase II):比較分析
・初期治験段階の薬剤(Phase I & IND Filed):比較分析
・薬剤候補のプロファイル
・Anti-CD19抗体の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・Anti-CD19抗体開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “Anti-CD19 Antibody-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD19 Antibody. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti-CD19 Antibody. DelveInsight’s Report also assesses the Anti-CD19 Antibody therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of Anti-CD19 Antibody
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Anti-CD19 Antibody pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Anti-CD19 Antibody and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Anti-CD19 Antibody Overview
• Anti-CD19 Antibody Disease Associated
• Anti-CD19 Antibody Pipeline Therapeutics
• Anti-CD19 Antibody Therapeutics under Development by Companies
• Anti-CD19 Antibody Filed and Phase III Products
• Comparative Analysis
• Anti-CD19 Antibody Phase II Products
• Comparative Analysis
• Anti-CD19 Antibody Phase I and IND Filed Products
• Comparative Analysis
• Anti-CD19 Antibody Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Anti-CD19 Antibody – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Anti-CD19 Antibody – Discontinued Products
• Anti-CD19 Antibody – Dormant Products
• Companies Involved in Therapeutics Development for Anti-CD19 Antibody
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Anti-CD19 Antibody by Therapy Area, 2017
• Number of Products under Development for Anti-CD19 Antibody, 2017
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2017
• Comparative Analysis Phase II Products, 2017
• Comparative Analysis Phase I and IND Filed Products, 2017
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
• Drug Candidates Profiles
• Anti-CD19 Antibody Assessment by Monotherapy Products
• Anti-CD19 Antibody Assessment by Combination Products
• Anti-CD19 Antibody Assessment by Route of Administration
• Anti-CD19 Antibody Assessment by Stage and Route of Administration
• Anti-CD19 Antibody Assessment by Molecule Type
• Anti-CD19 Antibody Assessment by Stage and Molecule Type
• Anti-CD19 Antibody Therapeutics – Discontinued Products
• Anti-CD19 Antibody Therapeutics – Dormant Products
• Products under Development by Companies, 2017


List of Figures
• Number of Products under Development for Anti-CD19 Antibody by Therapy Area, 2017
• Number of Products under Development for Anti-CD19 Antibody, 2017
• Filed and Phase III Products, 2017
• Phase II Products, 2017
• Phase I and IND Filed Products, 2017
• Discovery and Pre-Clinical Stage Products, 2017
• Anti-CD19 Antibody Assessment by Monotherapy Products
• Anti-CD19 Antibody Assessment by Combination Products
• Anti-CD19 Antibody Assessment by Route of Administration
• Anti-CD19 Antibody Assessment by Stage and Route of Administration
• Anti-CD19 Antibody Assessment by Molecule Type
• Anti-CD19 Antibody Assessment by Stage and Molecule Type


【レポートのキーワード】

Anti-CD19抗体、医薬品、製薬、研究開発、パイプライン、治療、治験

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Anti-CD19抗体のパイプライン・インサイト2017(Anti-CD19 Antibody -Pipeline Insights, 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆